Develops biotechnology platforms for cancer immunotherapy, focusing on antigen recognition and T-cell engagement.
Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in the development of innovative therapeutics for cancer and autoimmune diseases. At the forefront of its pipeline is SL-172154, the company's lead product candidate currently undergoing Phase 1 clinical trials. This therapy targets ovarian, fallopian tube, and peritoneal cancers, aiming to address critical unmet medical needs in oncology.
In addition to SL-172154, Shattuck Labs is advancing SL-279252 through Phase 1 clinical trials for patients with advanced solid tumors and lymphoma. This demonstrates the company's commitment to leveraging its proprietary technology platforms to develop novel treatments that target diseases with significant unmet patient needs.
Founded in 2016, Shattuck Labs has rapidly expanded its capabilities in biotechnology, focusing on harnessing the potential of its innovative pipeline to transform patient care. With a strong foundation in research and development, the company continues to pursue advancements in therapeutic options aimed at improving outcomes for cancer patients and those affected by autoimmune disorders.